CA3068355A1 - Methods for treating tumors - Google Patents

Methods for treating tumors Download PDF

Info

Publication number
CA3068355A1
CA3068355A1 CA3068355A CA3068355A CA3068355A1 CA 3068355 A1 CA3068355 A1 CA 3068355A1 CA 3068355 A CA3068355 A CA 3068355A CA 3068355 A CA3068355 A CA 3068355A CA 3068355 A1 CA3068355 A1 CA 3068355A1
Authority
CA
Canada
Prior art keywords
nanoparticle
nanoparticles
cells
tumor
nox5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068355A
Other languages
English (en)
French (fr)
Inventor
Francois Lux
Olivier Tillement
Jean-Luc Perfettini
Eric Deutsch
Frederic Law
Awatef Allouch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
NH Theraguix SA
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
NH Theraguix SA
Université Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Institut National de la Santé et de la Recherche Médicale, NH Theraguix SA, Université Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique
Publication of CA3068355A1 publication Critical patent/CA3068355A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3068355A 2017-07-05 2018-07-04 Methods for treating tumors Pending CA3068355A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305869.4A EP3424533A1 (en) 2017-07-05 2017-07-05 Methods for treating tumors
EP17305869.4 2017-07-05
PCT/EP2018/068099 WO2019008040A1 (en) 2017-07-05 2018-07-04 METHODS OF TREATING TUMORS

Publications (1)

Publication Number Publication Date
CA3068355A1 true CA3068355A1 (en) 2019-01-10

Family

ID=59363059

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068355A Pending CA3068355A1 (en) 2017-07-05 2018-07-04 Methods for treating tumors

Country Status (9)

Country Link
US (1) US20210128730A1 (enExample)
EP (2) EP3424533A1 (enExample)
JP (1) JP7386711B2 (enExample)
KR (1) KR102799910B1 (enExample)
CN (1) CN110913909A (enExample)
AU (1) AU2018296426B2 (enExample)
CA (1) CA3068355A1 (enExample)
TW (1) TWI796340B (enExample)
WO (1) WO2019008040A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
KR20220106736A (ko) 2019-07-29 2022-07-29 엔에이취 테라귁스 종양 치료 방법
FR3099883A1 (fr) 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
TWI833803B (zh) * 2019-09-12 2024-03-01 法商Ｎｈ蕾哈吉公司 含有高ｚ元素之奈米顆粒在製備用於治療腫瘤之藥物之用途
EP3795178A1 (en) 2019-09-19 2021-03-24 Nh Theraguix Methods for triggering m1 macrophage polarization
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy
WO2021228867A1 (en) 2020-05-15 2021-11-18 Universite Claude Bernard Lyon 1 Methods for image-guided radiotherapy
CA3084780A1 (en) * 2020-06-24 2021-12-24 Rodney HERRING Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases
FR3116197A1 (fr) 2020-11-19 2022-05-20 Nh Theraguix Procédé de traitement de tumeurs par captation du cuivre et/ou du fer
FR3116216B1 (fr) 2020-11-19 2023-10-27 Nh Theraguix Procédé de préparation de nanoparticules
CN120359049A (zh) 2022-07-13 2025-07-22 蒙彼利埃大学 纳米颗粒和放射性药物的联合疗法
CN120225206A (zh) * 2022-09-16 2025-06-27 株式会社韩国原子力工学 具有远端效应的用于预防或者治疗癌症的组合物，以及使用该组合物预防或者治疗癌症的方法
EP4605019A2 (en) 2022-10-18 2025-08-27 Nh Theraguix Methods for imaging using spcct
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
FR3151755A1 (fr) 2023-07-31 2025-02-07 Nh Theraguix Procédé de quantification de la concentration d’un agent de contraste et dispositif associé

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026748A2 (en) * 2000-09-25 2002-04-04 The Procter & Gamble Company Metal complexes for use in medical and therapeutic applications
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
FR2959502B1 (fr) * 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US9726661B2 (en) * 2012-07-06 2017-08-08 Institut Gustave-Roussy Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
PL2948179T3 (pl) * 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
KR101662755B1 (ko) * 2015-04-28 2016-10-05 한국생명공학연구원 Nox5의 발현 또는 활성을 억제하는 제제를 포함하는 암 치료용 조성물
JP2018516256A (ja) * 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
WO2016196894A1 (en) * 2015-06-03 2016-12-08 Kradl Therapeutics, Llc Compositions of polyunsaturated fatty acids and methods of use thereof

Also Published As

Publication number Publication date
JP2020525467A (ja) 2020-08-27
TW201906636A (zh) 2019-02-16
EP3648793A1 (en) 2020-05-13
EP3424533A1 (en) 2019-01-09
KR20200026290A (ko) 2020-03-10
TWI796340B (zh) 2023-03-21
KR102799910B1 (ko) 2025-04-25
US20210128730A1 (en) 2021-05-06
WO2019008040A1 (en) 2019-01-10
JP7386711B2 (ja) 2023-11-27
AU2018296426B2 (en) 2024-04-04
AU2018296426A1 (en) 2020-01-16
CN110913909A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
AU2018296426B2 (en) Methods for treating tumors
Du et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy
Jung et al. Overcoming the limits of hypoxia in photodynamic therapy: a carbonic anhydrase IX-targeted approach
Zheng et al. Metal nanoparticles as novel agents for lung cancer diagnosis and therapy
Cheng et al. Coassembly of hypoxia-sensitive macrocyclic amphiphiles and extracellular vesicles for targeted kidney injury imaging and therapy
Kim et al. Multifunctional trastuzumab–chlorin e6 conjugate for the treatment of HER2-positive human breast cancer
US20120095387A1 (en) Methods for detection, diagnosis and selective eradication of neoplasms in vivo using multidomain biotags
Mandl et al. Combining Pr3+-doped nanoradiosensitizers and endogenous protoporphyrin IX for X-ray-mediated photodynamic therapy of glioblastoma cells
Liu et al. One‐dose bioorthogonal gadolinium nanoprobes for prolonged radiosensitization of tumor
CN101313219B (zh) 一种诊断和治疗方法及其所使用的试剂
Tripathi et al. Biological Cargo: Exosomes and their Role in Cancer Progression and Metastasis
US20230218781A1 (en) Methods for triggering m1 macrophage polarization
Yang et al. Combination of porous Se@ SiO2 nanospheres and docetaxel exhibits anti-castration-resistant prostate cancer activity by downregulating ATG14-dependent autophagy
JP2006517032A (ja) ある種の癌治療の有効性を評価するための方法
JP2023529660A (ja) エクストラドメイン－ｂフィブロネクチン標的プローブを用いた診断及びモニタリング
Zhu et al. Injectable Cu2+ loaded rhein hydrogel for cross-amplifying osteosarcoma apoptosis and cuproptosis epitranscriptomically
Song et al. Gadolinium-Based Nanoparticles Combined with Checkpoint Blockade Amplify Radiation-Induced Abscopal Effect and Cancer Immunotherapy
Joshi et al. Exosome and other extracellular vesicles for cancer management
Zhang et al. 177Lu-Labeled Near-Infrared Upconversion Nanoparticles for Targeted Theranostics of Breast Cancer Lymphatic Metastases
Sitia et al. HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. Cancers 2022, 14, 2424
US20170176445A1 (en) Method for determining the level of hypoxia in a tumor
Kader Cellular and subcellular characterization of prostate carcinomas by molecular magnetic resonance imaging
WO2024236048A1 (en) Combination therapy for treating tumors with radiotherapy
Yang Early Detection of Breast Cancer Using Molecular Beacons
Chou The New Therapeutic Strategies for Improving the Efficacy and Reducing the Adverse Effects of Radiotherapy for Early Stage Prostate Cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260219